Skip to content

Depression research published in 2024

Page 24 of 26: studies 461 to 480 of 512, newest first. Back to the depression overview

Studies

Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression: A protocol for systematic review and meta-analysis.

PLoS One 2024 Michele F. Rodrigues, Larissa Junkes, Jose Appolinario et al. 5 citations

Major Depressive Disorder (MDD) is a global health issue, and a significant portion of individuals with MDD experience Treatment-Resistant Depression (TRD), characterized by the lack of response to adequately trialed antidepressant medication and therapy. This systematic review aims to investigate the effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) as an intervention for individuals...

Protocol for a Pilot Study on the Neurocardiac Mechanism of an Interoceptive Compassion-Based Heart-Smile Training for Depression.

Global Advances in Integrative Medicine and Health 2024 Eunmi Kim, Diane Joss, Frannie Marin et al. 1 citation

Heart-Smile Training (HST) is an interoceptive compassion-based behavioral intervention that in case reports has been beneficial for depression. Interoception refers to the awareness and regulation of physiological signals from inside the body. Depressed patients often have diminished interoceptive awareness and often experience disconnection from bodily needs and sensations. In addition to...

The impact of immersive virtual reality meditation for depression and anxiety among inpatients with major depressive and generalized anxiety disorders.

Frontiers in Psychology 2024 Jungjoo Lee, Junhyoung Kim, Marcia G Ory 23 citations

Mindfulness-Based Cognitive Therapy (MBCT) is a non-pharmacological approach to alleviating depression and anxiety. While technology based MBCT is a standardized cost-effective approach, there have been concerns about its feasibility and effectiveness in clinical settings. The purpose of this study was to investigate the longitudinal relationship between improved emotional regulation resulting...

DOI: 10.3389/fpsyg.2024.1471269 (opens in new tab) Full text (opens in new tab) Heartmath Emotional regulation Mental health Pilot study +1

Analysis of independent risk factors for postpartum depression in elderly primiparas and the effects of mindfulness-based psychological intervention.

American Journal of Translational Research 2024 Baihong Wu, Nan Wang, Lili Hu et al. 1 citation

To identify the independent risk factors for postpartum depression in elderly primiparas and to evaluate the effects of mindfulness-based psychological intervention. A retrospective analysis was conducted on 75 women with postpartum depression who received treatment at the First Hospital of Nanchang from January 2021 to March 2022. Among them, 33 women who received routine psychological health...

DOI: 10.62347/YEMU2258 (opens in new tab) Full text (opens in new tab) Anxiety Elderly primiparas Mindfulness-based psychological intervention Postpartum depression +1

The effectiveness of mindfulness-based stress reduction (MBSR) on depression, PTSD, and mindfulness among military veterans: A systematic review and meta-analysis.

Health Psychology Open 2024 Wendy Wen Li, Jaime Nannestad, Timothy Leow et al. 19 citations

Thirteen studies were included in the current systematic review and meta-analysis with 1131 participants. Both within- and between-group comparisons demonstrated reductions in depressive and PTSD symptoms with medium effect sizes post MBSR intervention. Additionally, MBSR demonstrated small effects in improving mindfulness in veterans at post-intervention. Maintenance of treatment effects were...

Effects of a Mindfulness-Based Intervention on Event-Related Potentials (P3) and Depressive Symptoms in Oncological Patients.

Integrative Cancer Therapies 2024 Theresa Schweig, Madeleine Fink, Kira Schmidt et al.

Objective: The aim of this study was to investigate changes in P3 amplitude and latency to emotional stimuli with different arousal and valence levels after a mindfulness-based intervention in oncological patients. Methods: P3 amplitude and latency at Fz, Cz, and Pz to emotional salient stimuli differing in valence (positive vs. negative) and arousal (low vs. high) levels were measured in 17...

Mindfulness and CBT: a conceptual integration bridging ancient wisdom and modern cognitive theories of psychopathology.

Frontiers in Psychology 2024 Shadi Beshai 7 citations

With the rapid expansion of mindfulness and its incorporation into the "third wave" of Cognitive Behavioral Therapy (CBT), there has been evident confusion about what mindfulness is and how it relates to this broader category of interventions. In this article, I define mindfulness and CBT, and differentiate them while highlighting their substantial overlap. Specifically, I discuss the Buddhist...

DOI: 10.3389/fpsyg.2024.1489798 (opens in new tab) Full text (opens in new tab) Depression Conceptual integration Dysfunctional attitudes Mindfulness-based interventions +1

Rumination and Self-Compassion Moderate Mindfulness-Based Cognitive Therapy for Patients With Recurrent and Persistent Major Depressive Disorder: A Controlled Trial.

Depression and Anxiety 2024 Jelle Lubbers, Dirk E. M. Geurts, Philip Spinhoven et al. 10 citations

Background: Mindfulness-based cognitive therapy (MBCT) is effective in reducing depressive symptoms in patients with major depressive disorder (MDD). Understanding for whom and how MBCT works may allow for improvements in treatment allocation and effectiveness. In this study, our aim was to investigate depressive rumination, content-independent perseverative thinking, mindfulness skills, and...

Emotion Regulation as a Mechanism of Mindfulness in Individual Cognitive-Behavioral Therapy for Depression and Anxiety Disorders.

Depression and Anxiety 2024 Luise Pruessner, Christina Timm, Julia Kalmar et al. 22 citations

The global prevalence of depression and anxiety disorders underscores the need for a more profound comprehension of effective treatments. Mindfulness has shown promise in enhancing treatment outcomes and preventing relapse in these conditions, but the underlying mechanisms remain poorly understood. This study examined the role of emotion regulation as a mediator in the relationship between...

Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression.

Frontiers in Psychiatry 2024 Aleksander Kwaśny, Wiesław Jerzy Cubała, Adam Włodarczyk 7 citations

Anhedonia is a core symptom of depression characterized by a diminished ability to experience pleasure. Currently available treatments for depression often fall short in adequately addressing anhedonia that often presents as a chronic and debilitating symptom. Ketamine is known to possess antianhedonic properties. This post-hoc analysis of a naturalistic observational study of...

Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression.

Therapeutic Advances in Psychopharmacology 2024 Raymond Yan, Tyler Marshall, Atul Khullar et al. 11 citations

Intravenous (IV) ketamine is a rapid acting antidepressant used primarily for treatment-resistant depression (TRD). It has been suggested that IV ketamine's rapid antidepressant effects may be partially mediated via improved sleep and changes to the circadian rhythm. This study explores IV ketamine's association with changes in patient-reported sleep quality and circadian rhythm in an adult...

Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis.

Frontiers in Psychiatry 2024 Alexandros Matsingos, Marcel Wilhelm, Laila Noor et al. 18 citations

Ketamine and esketamine offer a novel approach in the pharmacological treatment of major depressive disorder (MDD). This meta-analysis aimed to investigate the placebo response in double-blind, randomized controlled studies (RCTs) on patients with MDD receiving ketamine or esketamine. For this systematic review and meta-analysis Medline (PubMed), Cochrane Central Register of Controlled Trials...

Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report.

Brain Stimulation 2024 Charles R Conway, Scott T Aaronson, Harold A Sackeim et al. 16 citations

RECOVER is a randomized sham-controlled trial of vagus nerve stimulation and the largest such trial conducted with a psychiatric neuromodulation intervention. To describe pre-implantation baseline clinical characteristics and treatment history of patients with unipolar, major depressive disorder (MDD), overall and as a function of exposure to interventional psychiatric treatments (INTs),...

DOI: 10.1016/j.brs.2024.03.016 (opens in new tab) Full text (opens in new tab) Esketamine Electroconvulsive therapy Recover trial Treatment-resistant depression trd +7

Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications.

Frontiers in Pharmacology 2024 Senbing Zhang, Yanzhu Pu, Jianning Liu et al. 12 citations

(R, S)- and (S)-ketamine have made significant progress in the treatment of treatment-resistant depression (TRD) and have become a research focus in recent years. However, they both have risks of psychomimetic effects, dissociative effects, and abuse liability, which limit their clinical use. Recent preclinical and clinical studies have shown that (R)-ketamine has a more efficient and lasting...

DOI: 10.3389/fphar.2024.1337749 (opens in new tab) Full text (opens in new tab) R-ketamine Antidepressant efficacy Cognitive disorders Ischemic stroke +6

Psychiatric and legal considerations for ketamine treatment within prison settings.

Frontiers in Psychiatry 2024 Michael Bayrhammer-Savel, Martin Ortner, Marie Claire Van Hout et al. 6 citations

The fundamental right to equivalence of health care in prison settings encompasses the provision of medication to address mental health conditions. Considering the increased risk for self-harm among individuals dealing with depression, the limited effectiveness of conservative antidepressants is a major challenge in psychiatry. The high prevalence of suicidal tendencies within prison...

Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?

Frontiers in Psychiatry 2024 Magdalena Więdłocha, Piotr Marcinowicz, Jan Komarnicki et al. 4 citations

Borderline personality disorder (BPD) is diagnosed in 10-30% of patients with major depressive disorder (MDD), and the frequency of MDD among individuals with BPD reaches over 80%. The comorbidity of MDD and BPD is associated with more severe depressive symptoms and functional impairment, higher risk of treatment resistance and increased suicidality. The effectiveness of ketamine usage in...

A qualitative investigation of the Montgomery-Åsberg depression rating scale: discrepancies in rater perceptions and data trends in remote assessments of rapid-acting antidepressants in treatment resistant depression.

Frontiers in Psychiatry 2024 Gianna Capodilupo, Raymond Blattner, Anita Must et al. 3 citations

Despite the development of many successful pharmaceutical interventions, a significant subset of patients experience treatment-resistant depression (TRD). Ketamine and its derivatives constitute a novel therapeutic approach to treat TRD; however, standard tools, such as the Montgomery-Åsberg Depression Rating Scale (MADRS) are still being used to measure symptoms and track changes. The aim of...

DOI: 10.3389/fpsyt.2024.1289630 (opens in new tab) Full text (opens in new tab) Rapid acting antidepressants Rater perception Depression treatment Clinical assessment scales +3

Comparison of Effects of Propofol Combined with Different Doses of Esketamine for ECT in the Treatment of Depression: A Randomized Controlled Trial Protocol.

Neuropsychiatric Disease and Treatment 2024 Xuemeng Chen, Rui Zhou, Lan Lan et al. 4 citations

Major depressive disorder (MDD) is a common mood disorder. Electroconvulsive therapy (ECT) has a significant effect on treatment-resistant MDD. Esketamine may have potential advantages in improving the efficacy of ECT, and the strong affinity of this compound for NMDAR renders it a viable therapeutic option for the management of depression. This study aims to compare the effects of different...

DOI: 10.2147/NDT.S463028 (opens in new tab) Full text (opens in new tab) Depressive disorder Curative effect Electroconvulsive therapy Depression therapy +4

Effects of esketamine and fluoxetine on depression-like behaviors in chronic variable stress: a role of plasma inflammatory factors.

Frontiers in Psychiatry 2024 Haixia Chen, Xinxin Zhao, Xinxu Ma et al. 9 citations

Mounting evidence has identified the rapid and sustained antidepressive and anxiolytic-like effects of esketamine. However, the underlying mechanism of this no-monoamine target rapid-onset antidepressant is still underexplored. Immune-inflammatory pathways and cell-mediated immune activation, mainly including inflammatory cytokines in plasma, play a pivotal role in the pathogenesis of major...

Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review.

Frontiers in Psychiatry 2024 Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca et al. 31 citations

Treatment-resistant depression (TRD) occurs when at least two different antidepressants, taken at the right dosage, for adequate period of time and with continuity, fail to give positive clinical effects. Esketamine, the S-enantiomer of ketamine, was recently approved for TRD treatment from U.S. Food and Drug Administration and European Medicine Agency. Despite proved clinical efficacy, many...